MindWalk Holdings (HYFT) Income from Continuing Operations (2020 - 2026)
MindWalk Holdings (HYFT) reported Income from Continuing Operations of 32527.24 for Q1 2026, up 100.18% year-over-year from 16248.71 in Q1 2025, and up 100.0% quarter-over-quarter from 2922414643.1 in Q4 2025.
MindWalk Holdings (HYFT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 7 years of Income from Continuing Operations data on file, last reported at 32527.24 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 32527.24, up 100.18% year-over-year; the trailing twelve-month figure through Jan 2026 was 3149380323.6 (up 12.44% YoY), and the FY2025 annual result was 21704604.99, down 12.69% from the prior year.
- Income from Continuing Operations improved to 32527.24 in Q1 2026 per HYFT's latest filing, from 2922414643.1 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 32527.24 in Q1 2026 and troughed at 3562461814.32 in Q3 2024.
- A 5-year average of 397881630.32 and a median of 2451436.98 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations plunged 117436228.88% in 2024, then surged 100.18% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 5.89 in 2022, then tumbled by 37847040.45% to 2229444.02 in 2023, then soared by 96.09% to 87145.32 in 2024, then slumped by 3353395.64% to 2922414643.1 in 2025, then soared by 100.0% to 32527.24 in 2026.
- Business Quant data shows HYFT's Income from Continuing Operations at 32527.24 in Q1 2026, 2922414643.1 in Q4 2025, and 3550.14 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | 32,527.24 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | 32,527.24 |
| Oct 31, 2025 | -2.92 Bn |
| Jul 31, 2025 | -3,550.14 |
| Apr 30, 2025 | -226.99 Mn |
| Jan 31, 2025 | -17.72 Mn |
| Oct 31, 2024 | -87,145.32 |
| Jul 31, 2024 | -3.56 Bn |
| Apr 30, 2024 | -16.47 Mn |
| Jan 31, 2024 | -2.45 Mn |
| Oct 31, 2023 | -2.23 Mn |
| Jul 31, 2023 | -3,033.53 |
| Apr 30, 2023 | -6.39 Mn |
| Jan 31, 2023 | -3.40 Mn |
| Oct 31, 2022 | -5.89 |
| Jul 31, 2022 | -7,892.68 |
| Apr 30, 2022 | -3.38 Mn |
| Jan 31, 2022 | -3,478.73 |
| Oct 31, 2021 | -3,837.99 |
| Jul 31, 2021 | -67,125.93 |
| Apr 30, 2021 | -2.46 Mn |